Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs ProShares Ultra Gold ETF — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B), while ProShares Ultra Gold ETF trades at $46.45 (market cap $716.59M). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 82× ProShares Ultra Gold ETF's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days and ProShares Ultra Gold ETF for 23 Days on average.
| TAK | UGL | |
|---|---|---|
Market Cap | $58.74B | $716.59M |
Volume | 3,110,994 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $19.05 | $85.62 |
52-Week Low | $13.23 | $42.79 |
Typical Hold Time | 1 Days | 23 Days |
Enterprise Value | $86.65B | — |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UGL trades at $45.08, up 1.46% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Support is clustered around $44-$45, while resistance sits near $46. Recent news highlights gold's volatility amid shifting Fed rate expectations and Treasury yield pressures, impacting gold-related equities.
The outlook remains cautious due to weak technical momentum and macroeconomic headwinds like rising yields. Upside depends on sustained gold price recovery, but near-term risks from Fed policy and dollar strength suggest limited bullish catalysts. Investors should weigh the stock's sensitivity to commodity cycles against current bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
